DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

DBVT has been the topic of several other research reports. HC Wainwright boosted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $4.30 on Tuesday. The firm has a market cap of $88.45 million, a price-to-earnings ratio of -0.96 and a beta of 0.67. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.09. The firm has a 50 day moving average price of $3.95 and a two-hundred day moving average price of $3.84.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.